Non-vitamin K antagonist oral anti-coagulation agents (NOACs) for the treatment and secondary prevention of venous thromboembolism

Published on 05 Feb 2018
Last Updated on 01 Jul 2022

Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has recommended:

• Rivaroxaban 15 mg and 20 mg tablets, and apixaban 2.5 mg and 5 mg tablets for adults to:

  • treat deep vein thrombosis (DVT) and pulmonary embolism (PE); and

  • prevent recurrent DVT and PE.

Subsidy status

Rivaroxaban 15 mg and 20 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indications.

MAF assistance do not apply to the following:

• the use of rivaroxaban for isolated distal DVT; or

• rivaroxaban 2.5 mg and 10 mg tablets.

Apixaban 2.5 mg and 5 mg tablets are recommended for reclassification from MAF to the MOH Standard Drug List (SDL).

SDL subsidy or MAF assistance do not apply to any strengths of dabigatran.

NOACs for the treatment and secondary prevention of venous thromboembolism (1 Jul 22) [PDF, 130 KB]

PES Anticoagulants to treat and prevent blood clots (Published 1 July 2022) [PDF, 141 KB]